title: New perspectives on the development of antiobesity drugs.
abstract: After many years of research, obesity is still a disease with an unmet medical need. Very few compounds have been approved, acting mainly on neuromediators; researches, in recent years, pointed toward compounds potentially safer than first-generation antiobesity drugs, able to interact with one or more (multitarget therapy) receptors for substances produced by the gut, adipose tissue and other targets outside CNS. Other holistic approaches, such as those involving gut microbiota and plant extracts, appeared recently in the literature, and undoubtedly will contribute to the discovery of a valuable therapy for this disease. This review deals with the positive results and the pitfalls obtained following these approaches, with a view on their clinical trial studies.
authors.affiliation: University of Modena & Reggio Emilia, Dipartimento di Scienze della Vita, Via Campi 183, 41100 Modena, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Costantino
authors.forename: Daniela
authors.initials: D
authors.lastname: Barlocco
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D015394:Molecular Structure; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents